Read Our Recent News
NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for European clinical trial programme
NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for European clinical trial programme Precision oncology therapeutics company moves centre of operations from China London, April 28, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, today announced a number of key management changes. The company has also established a UK subsidiary office and moved its centre of operations as it prepares to start clinical trials for [...]
NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02
Date: Aug 13th, 2019 NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02 Shanghai, China, August 13th, 2019. NanoMab today announced dosing of the first patients for its FIH trial of 99mTc-NM-02 in patients with breast cancer at SGH. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients before or during HER2 targeted treatment
NanoMab To Initiate FIH for 99mTc-NM-02 at SGH
Date: Aug 1st, 2019 NanoMab To Initiate FIH for 99mTc-NM-02 at SGH Shanghai, China, August 1st, 2019. NanoMab announced that it has decided to initiate FIH with 99mTc-NM-02, which is the company’s breast cancer program. The kick off meeting was held at Shanghai General Hospital (SGH). The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of 99mTc-NM-02. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients [...]
NanoMab Presents at SNMMI
Date: June 24th, 2019 NanoMab Presents at SNMMI Anaheim, California, US, June 24th, 2019. Gitasha Chand, clinical research director of NanoMab presented NanoMab’s FIH data of 99mTc-NM-01 at the annual meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI). 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment Also see link: Early phase I study of a 99m Tc labeled anti-PD-L1 sdAb in SPECT/CT [...]
NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01
Date: May 29th, 2019 NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01 Shanghai, China, May 29th, 2019. NanoMab announced a collaboration with Lantheus Medical Imaging, Inc. (LMI) to provide 99mTc-NM-01 as clinical research tool, together with support and analytics, to pharmaceutical companies and the largest academic centers conducting clinical research in immuno-oncology in North America and Europe. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in [...]
Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society
Date: April 1st-3rd, 2019 Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society London, UK, April 1st-3rd, 2019. Gary Cook, scientific advisor of NanoMab presented 99mTc-NM-01 clinical data at the annual meeting of British Nuclear Medicine Society (BNMS) and was awarded with 2nd Oral Prize for his presentation ‘Imaging Programmed Cell Death Ligand-1 (PDL1) Expression in Non-Small Cell Lung Cancer with 99mTc anti PDL1 sdAb SPECT’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and [...]